As anticipated, Trastuzumab-SB-Saporin had no impact on the viability of Her2-low MDA-MB-231 basal breast cancer cells (Fig. 1c) or on other Her2-low cell lines or on monocytic cell lines expressing Fcγ receptors (Supplementary Fig. 2). The gene discussed is ERBB2; the disease is breast cancer.